MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells
Arabinda Das, Fraser Henderson, Mohammed Alshareef, Guilherme Porto, Indira Kanginakudru, Libby Kosnik Infinger, William A. Vandergrift, Scott Lindhorst, Abhay Varma, Sunil J. Patel, David Cachia
Topics & Concepts
TemozolomideMedicineMethyltransferaseCancer researchPI3K/AKT/mTOR pathwayViability assayCyclin-dependent kinaseO-6-methylguanine-DNA methyltransferasePharmacologyGliomaCell cycleSignal transductionBiologyCellInternal medicineMethylationCancerCell biologyGeneticsBiochemistryGeneGlioma Diagnosis and TreatmentTGF-β signaling in diseasesAdvanced Breast Cancer Therapies